Ribo’s siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia

On October 28, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3. The trial will evaluate efficacy and safety in patients with mixed dyslipidemia. A randomized, […]

First Patient Dosed at Ribocure Clinic

With the ambition to become a world-leading clinical oligonucleotide research company, Ribocure Pharmaceuticals AB has established Ribocure Clinic, to focus on high-quality Proof of Principle Ph2 studies. The clinic has now dosed its first patient in a Phase 2 study using the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, RBD4059. Ribocure Clinic, […]

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) have entered a strategic partnership with Pheiron to leverage its cutting-edge AI platform, PheironGPS, in Ribo’s discovery and development of RNA-based therapeutics. This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology. PheironGPS […]

Ribo presented the first clinical data from our completed Ph1 study of the world’s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.

We thank the European Society of Cardiology #ESC Congress, session chairs, and all participants in the session for the opportunity and attention. We look forward to continuing the further clinical development of RBD4059 based on our Phase 1 results. “We are excited to have progressed world’s first and most advanced FXI siRNA program, now into […]

Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the world’s first siRNA drug targeting Factor XI: RBD4059

On May 27, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the world’s first and most advanced anti-thrombotic siRNA drug, RBD4059 targeting FXI. The trial will evaluate safety, pharmacokinetics and pharmacodynamics of its […]

Join us in celebrating Clinical Trials Day!

Today we highlight the Clinical Trials Day and the importance of clinical research at Ribocure Pharmaceuticals and Ribocure Clinic. Ribocure Clinic is our specialized clinical trial unit with highly trained medical research staff for Phase 2 trials in cardiovascular, pulmonary, renal and liver disease, where advanced imaging and functional assessments are applied. Read more about […]

Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe

Ribocure Pharmaceuticals/Suzhou Ribo Life Science Co. Ltd. (“Ribo”) announce Notice of Allowance issued respectively by US Patent Office and European Patent Office for patent applications covering the anti-hepatitis B siRNA drug RBD1016. With the approved patents in US and Europe, and with the previous authorizations in six major countries/regions, including China and Japan, Ribo’s strategy […]

Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)

On April 10, 2024, Ribo and Ribocure announce the completion of enrolment and dosing of the Ph1 clinical trial with world’s first and most advanced anti-thrombotic siRNA drug, RBD4059, targeting coagulation factor XI (FXI). The Phase I clinical trial is a randomized, single-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and potency of RBD4059 […]

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
 
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
 
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
 
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
 
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
 
Contact information to the Data Protection Officer (DPO):
 
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
Sweden
 
E-mail: dpo@ribocure.com